Your browser doesn't support javascript.
loading
NMNAT2 supports vesicular glycolysis via NAD homeostasis to fuel fast axonal transport.
Yang, Sen; Niou, Zhen-Xian; Enriquez, Andrea; LaMar, Jacob; Huang, Jui-Yen; Ling, Karen; Jafar-Nejad, Paymaan; Gilley, Jonathan; Coleman, Michael P; Tennessen, Jason M; Rangaraju, Vidhya; Lu, Hui-Chen.
Afiliação
  • Yang S; Indiana University Bloomington.
  • Niou ZX; Indiana University Bloomington.
  • Enriquez A; Indiana University Bloomington.
  • LaMar J; Florida Atlantic University.
  • Huang JY; Indiana University Bloomington.
  • Ling K; Ionis Pharmaceuticals Inc.
  • Jafar-Nejad P; Ionis Pharmaceuticals Inc.
  • Gilley J; Cambridge University: University of Cambridge.
  • Coleman MP; Cambridge University: University of Cambridge.
  • Tennessen JM; Indiana University Bloomington.
  • Rangaraju V; Max Planck Florida Institute for Neuroscience.
  • Lu HC; Indiana University Bloomington.
Res Sq ; 2023 May 19.
Article em En | MEDLINE | ID: mdl-37292715
Background: Bioenergetic maladaptations and axonopathy are often found in the early stages of neurodegeneration. Nicotinamide adenine dinucleotide (NAD), an essential cofactor for energy metabolism, is mainly synthesized by Nicotinamide mononucleotide adenylyl transferase 2 (NMNAT2) in CNS neurons. NMNAT2 mRNA levels are reduced in the brains of Alzheimer's, Parkinson's, and Huntington's disease. Here we addressed whether NMNAT2 is required for axonal health of cortical glutamatergic neurons, whose long-projecting axons are often vulnerable in neurodegenerative conditions. We also tested if NMNAT2 maintains axonal health by ensuring axonal ATP levels for axonal transport, critical for axonal function. Methods: We generated mouse and cultured neuron models to determine the impact of NMNAT2 loss from cortical glutamatergic neurons on axonal transport, energetic metabolism, and morphological integrity. In addition, we determined if exogenous NAD supplementation or inhibiting a NAD hydrolase, sterile alpha and TIR motif-containing protein 1 (SARM1), prevented axonal deficits caused by NMNAT2 loss. This study used a combination of genetics, molecular biology, immunohistochemistry, biochemistry, fluorescent time-lapse imaging, live imaging with optical sensors, and anti-sense oligos. Results: We provide in vivo evidence that NMNAT2 in glutamatergic neurons is required for axonal survival. Using in vivo and in vitro studies, we demonstrate that NMNAT2 maintains the NAD-redox potential to provide "on-board" ATP via glycolysis to vesicular cargos in distal axons. Exogenous NAD+ supplementation to NMNAT2 KO neurons restores glycolysis and resumes fast axonal transport. Finally, we demonstrate both in vitro and in vivo that reducing the activity of SARM1, an NAD degradation enzyme, can reduce axonal transport deficits and suppress axon degeneration in NMNAT2 KO neurons. Conclusion: NMNAT2 ensures axonal health by maintaining NAD redox potential in distal axons to ensure efficient vesicular glycolysis required for fast axonal transport.

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2023 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2023 Tipo de documento: Article